Novartis takes next step in Russia, halting new trials and enrollment as Big Pharma responds to Ukraine invasion

After Novartis announced it was trimming down some of its business activities in Russia, the global pharma is taking the next step — and this time, it’s more in lockstep with other companies in the industry.